Affiliation:
1. Faculty of Health Sciences and Medicine University of Lucerne Lucerne Switzerland
2. Cancer Registry Bern Solothurn University of Bern Bern Switzerland
3. Department of Oncology University Children's Hospital Zurich Zurich Switzerland
4. Division of Pediatric Hematology/Oncology Children's Hospital of Eastern Switzerland St. Gallen Switzerland
5. Department of Pediatrics McMaster Children's Hospital and McMaster University Hamilton Ontario Canada
6. Swiss Childhood Cancer Registry Institute of Social and Preventive Medicine, University of Bern Bern Switzerland
7. Division of Pediatric Hematology/Oncology, Department of Pediatrics Inselspital, Bern University Hospital, University of Bern Bern Switzerland
Abstract
AbstractPurposeChildhood cancer and its treatment can cause damage to the musculoskeletal system. We aimed to determine the incidence and prevalence of musculoskeletal health conditions (MSHC) in survivors, and to investigate differences by cancer‐related characteristics.MethodsWe used data from the Childhood Cancer Registry and the Swiss Childhood Cancer Survivor Study, including survivors (≥5 years since diagnosis; diagnosed 1976–2015 at <20 years of age) aged ≥15 years at study. Cumulative incidence and prevalence of MSHCs (osteoporosis, limb length discrepancy, limited joint mobility, bone/joint pain, scoliosis, changes to chest/ribs and amputation) were calculated from self‐reported data.ResultsWe included 2645 survivors (53% men; median age 24 years, range 15–59 years). Prevalence and cumulative incidence of any MSHC was 21% and 26%, respectively. Incidence rate for any MSHC was 15.6/1000 person‐years. Scoliosis (8%), bone/joint pain (7%) and limited joint mobility (7%) were the most prevalent MSHC. MSHC co‐occurred with other health conditions in 87% of survivors. We found increased rates of MSHC in women (RR = 1.4, 95%CI: 1.2–1.7), bone tumour survivors (RR = 6.0, 95%CI: 4.5–7.9), survivors older at diagnosis (11–15 years: RR = 1.8, 95%CI: 1.5–2.3), after a relapse (RR = 1.5, 95%CI: 1.3–1.9), treatment with surgery (RR = 1.2, 95%CI: 1.0–1.5), chemotherapy (RR = 1.4, 95%CI: 1.1–1.8) or stem cell transplantation (RR = 1.6, 95%CI: 1.0–2.5), and more recent year of diagnosis (2011–2015: RR = 4.3, 95%CI: 2.8–6.8).ConclusionMSHCs are prevalent in survivors, the risk is increasing in younger survivor cohorts, and MSHCs usually occur in multimorbid survivors. Strengthening of rehabilitation services and appropriate referrals are needed to mitigate the effects of the cancer and cancer treatment.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献